A moving target: challenges in treating BRAF-mutant colorectal cancer
- 1 June 2013
- journal article
- Published by Taylor & Francis in Colorectal Cancer
- Vol. 2 (3) , 197-204
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Raf kinases in cancer–roles and therapeutic opportunitiesOncogene, 2011
- Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancerCancer Treatment Reviews, 2010
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerProceedings of the National Academy of Sciences, 2010
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma ModelsCancer Research, 2010
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- Distinct Sets of Genetic Alterations in MelanomaNew England Journal of Medicine, 2005
- Mutational analysis of the ARAF gene in human cancersAPMIS, 2005
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFCell, 2004
- Mutations of the BRAF gene in human cancerNature, 2002